Current stage -Stage IV Posts on Medivizor
Navigation Menu

Current stage -Stage IV Posts on Medivizor

Searching for patients with metastatic castration resistant prostate cancer to trial a biological treatment combination

Searching for patients with metastatic castration resistant prostate cancer to trial a biological treatment combination

Posted by on Aug 15, 2020 in Prostate cancer | 0 comments

In a nutshell This trial is examining the effectiveness of cabozantinib (Cabometyx) combined with atezolizumab (Tecentriq) for metastatic castration-resistant prostate cancer (mCRPC; cancer that is no longer responding to hormone therapy). The main outcomes to be measured are progression-free survival (PFS) and overall survival (OS) of...

Read More

Can androgen deprivation therapy combined with docetaxel plus prednisone improved outcomes in patients with metastatic hormone-sensitive prostate cancer?

Can androgen deprivation therapy combined with docetaxel plus prednisone improved outcomes in patients with metastatic hormone-sensitive prostate cancer?

Posted by on Jul 26, 2020 in Prostate cancer | 0 comments

In a nutshell The aim of this study was to evaluate the safety and effectiveness of combining androgen deprivation therapy (ADT) with docetaxel (Taxotere) plus prednisone (Deltasone) in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The study found that this combination improved the outcomes of these...

Read More

How long should hormonal treatment be given to patients with locally advanced prostate cancer?

Posted by on Apr 14, 2020 in Prostate cancer | 0 comments

In a nutshell This study compared 6-month and 18-month courses of hormonal anti-androgen treatment and radiotherapy (RT) in patients with locally advanced prostate cancer (LAPC). The results showed that 18-month treatment was most effective, especially when used with high dose brachytherapy RT. Some background Androgens (such as testosterone) are...

Read More

Quality of life in patients with advanced prostate cancer after apalutamide treatment

Posted by on Jan 12, 2020 in Prostate cancer | 0 comments

In a nutshell This study analyzed the health-related quality of life (HRQOL) in patients with metastatic castration-sensitive prostate cancer (MCSPC) after treatment with apalutamide (Erleada) and androgen deprivation therapy (ADT). The study found that apalutamide plus ADT was well tolerated and improved survival compared to ADT alone in these...

Read More

Evaluating the order of hormone therapy drugs for patients with prostate cancer

Posted by on Jan 5, 2020 in Prostate cancer | 0 comments

In a nutshell This study evaluated the order of treatment with two different hormone therapy drugs in patients with castration-resistant prostate cancer that has spread. This study found that treatment with abiraterone acetate (Yonsa) then enzalutamide (Xtandi) delayed cancer growth or spread longer than the same drugs in the opposite...

Read More

Abiraterone acetate and prednisone in patients with metastatic, castration‑sensitive prostate cancer

Posted by on Dec 30, 2019 in Prostate cancer | 0 comments

In a nutshell This study evaluated if the benefit of adding abiraterone acetate (Zytiga) + prednisone (Deltasone) to androgen-deprivation therapy (ADT) in treating metastatic, castration-sensitive prostate cancer (mCSPC) would be maintained in patients treated with ADT alone. This study concluded that this treatment...

Read More

Evaluating the safety of re-treatment with radium-223

Posted by on Sep 16, 2019 in Prostate cancer | 0 comments

In a nutshell This study aimed to evaluate the safety and effectiveness of radium-223 (Xofigo, formerly known as Alpharadin) in patients with advanced prostate cancer that has spread to the bones and who have had this treatment previously. This study found that re-treatment with radium-223 was well tolerated and with good results. Some background...

Read More

Evaluating enzalutamide plus androgen deprivation therapy to treat metastatic prostate cancer

Posted by on Aug 31, 2019 in Prostate cancer | 0 comments

In a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) with androgen deprivation therapy (ADT) in metastatic prostate cancer. This study found that this combination was associated with longer progression-free and overall survival compared to ADT alone. Some background Patients...

Read More